Elicio Therapeutics, Inc. (ELTX) — 8-K Filings

8-K Filings (26)

• Elicio Therapeutics Files 8-K — Sep 17, 2025 Risk: low
  Elicio Therapeutics, Inc. filed an 8-K on September 17, 2025, reporting on other events and financial statements. The company, formerly known as Angion Biomedic
• Elicio Therapeutics Files 8-K — Aug 12, 2025 Risk: medium
  Elicio Therapeutics, Inc. filed an 8-K on August 12, 2025, reporting an event under 'Other Events'. The company, formerly known as Angion Biomedica Corp. until
• Elicio Therapeutics Files 8-K — Aug 5, 2025 Risk: medium
  Elicio Therapeutics, Inc. filed an 8-K on August 5, 2025, reporting an "Other Events" item. The company, formerly known as Angion Biomedica Corp. until February
• Elicio Therapeutics Files 8-K: Material Agreement, Debt, Equity Sales — Jun 4, 2025 Risk: medium
  Elicio Therapeutics, Inc. announced on June 3, 2025, that it entered into a material definitive agreement. The company also disclosed the creation of a direct f
• Elicio Therapeutics Files 8-K on Shareholder Matters — May 20, 2025 Risk: low
  Elicio Therapeutics, Inc. filed an 8-K on May 20, 2025, reporting on the submission of matters to a vote of security holders. The filing indicates a change in t
• Elicio Therapeutics Reports Officer and Director Changes — Mar 24, 2025 Risk: medium
  Elicio Therapeutics, Inc. filed an 8-K on March 24, 2025, reporting changes effective March 21, 2025. The filing covers the departure of directors or certain of
• Elicio Therapeutics Files 8-K on Equity Sales — Mar 5, 2025 Risk: medium
  Elicio Therapeutics, Inc. filed an 8-K on March 5, 2025, reporting on unregistered sales of equity securities. The company, formerly known as Angion Biomedica C
• Elicio Therapeutics Enters Material Definitive Agreement — Jan 30, 2025 Risk: medium
  Elicio Therapeutics, Inc. announced on January 29, 2025, that it entered into a material definitive agreement. The company, formerly known as Angion Biomedica C
• Elicio Therapeutics Files 8-K — Jan 23, 2025 Risk: low
  Elicio Therapeutics, Inc. filed an 8-K on January 23, 2025, reporting a Regulation FD Disclosure. The company, formerly known as Angion Biomedica Corp. until Fe
• Elicio Therapeutics Files 8-K — Jan 22, 2025 Risk: medium
  Elicio Therapeutics, Inc. filed an 8-K on January 22, 2025, reporting an event under 'Other Events'. The company, formerly known as Angion Biomedica Corp. until
• Elicio Therapeutics Files 8-K — Dec 12, 2024 Risk: low
  Elicio Therapeutics, Inc. filed an 8-K on December 12, 2024, reporting under Regulation FD Disclosure and Other Events. The company, formerly known as Angion Bi
• Elicio Therapeutics Files 8-K — Dec 3, 2024 Risk: low
  Elicio Therapeutics, Inc. filed an 8-K on December 3, 2024, to report other events and financial statements. The company, formerly known as Angion Biomedica Cor
• Elicio Therapeutics Files 8-K on Security Holder Vote Matters — Nov 21, 2024 Risk: low
  Elicio Therapeutics, Inc. filed an 8-K on November 21, 2024, to report on the submission of matters to a vote of security holders. The company, formerly known a
• Elicio Therapeutics Files 8-K: Other Event Reported — Nov 7, 2024 Risk: medium
  Elicio Therapeutics, Inc. filed an 8-K on November 7, 2024, reporting an "Other Event." The filing does not contain specific details about the event itself, but
• Elicio Therapeutics Appoints New Directors, Updates Exec Compensation — Oct 17, 2024 Risk: medium
  Elicio Therapeutics, Inc. announced on October 15, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two new
• Elicio Therapeutics Director Resigns — Aug 30, 2024 Risk: medium
  Elicio Therapeutics, Inc. announced on August 27, 2024, a change in its board of directors. Specifically, Dr. Jonathan M. Rothberg has resigned from his positio
• Elicio Therapeutics Reports Material Definitive Agreement — Aug 12, 2024 Risk: medium
  Elicio Therapeutics, Inc. announced on August 12, 2024, that it entered into a material definitive agreement. The company also reported the creation of a direct
• Elicio Therapeutics Enters Material Definitive Agreement — Jul 1, 2024 Risk: medium
  Elicio Therapeutics, Inc. announced on June 28, 2024, that it entered into a Material Definitive Agreement. The company, formerly known as Angion Biomedica Corp
• 8-K Filing — Jun 27, 2024
• Elicio Therapeutics to be Acquired by Angion Biomedica — May 24, 2024 Risk: medium
  Elicio Therapeutics, Inc. announced on May 23, 2024, that it has entered into a definitive agreement to be acquired by Angion Biomedica Corp. The transaction is
• Elicio Therapeutics to be Acquired by Angion Biomedica — Apr 5, 2024 Risk: medium
  Elicio Therapeutics, Inc. announced on April 5, 2024, that it has entered into a definitive agreement to be acquired by Angion Biomedica Corp. The transaction i
• Elicio Therapeutics Enters Material Definitive Agreement — Mar 18, 2024 Risk: medium
  Elicio Therapeutics, Inc. announced on March 18, 2024, that it has entered into a Material Definitive Agreement. The company, formerly known as Angion Biomedica
• Elicio Therapeutics Amends Officer Compensation on Feb 1, 2024 — Feb 2, 2024
  Elicio Therapeutics, Inc. announced on February 1, 2024, that it has entered into new compensatory arrangements with certain officers, specifically regarding th
• Elicio Opts Out of EGC Accounting Transition Period — Jan 17, 2024
  Elicio Therapeutics, Inc. filed an 8-K on January 17, 2024, indicating it is an "emerging growth company" and has elected not to use the extended transition per
• Elicio Therapeutics Confirms Nasdaq Global Select Listing — Jan 16, 2024
  Elicio Therapeutics, Inc. filed an 8-K on January 16, 2024, to update its registration information, specifically noting its common stock is traded on The Nasdaq
• Elicio Therapeutics Updates Nasdaq Ticker to ELTX — Jan 9, 2024
  Elicio Therapeutics, Inc. filed an 8-K on January 9, 2024, to update its trading symbol from its previous symbol to ELTX on The Nasdaq Global Select Market. Thi

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX